Literature DB >> 9778529

A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.

L S Quek1, J Bolen, S P Watson.   

Abstract

Bruton's tyrosine kinase (Btk) is essential for normal B-cell receptor signalling. The lack of expression of functional Btk in humans leads to the B-cell deficiency X-linked agammaglobulinaemia (XLA). We report here that Btk is also important for signalling via the collagen receptor glycoprotein VI (GPVI) in platelets. GPVI is coupled to the Fc receptor gamma chain (FcRgamma). The FcRgamma-chain contains a consensus sequence known as the immune-receptor tyrosine-based activation motif (ITAM). Tyrosine phosphorylation of the ITAM upon GPVI stimulation is the initial step in the regulation of phospholipase C gamma2 (PLCgamma2) isoforms via the tyrosine kinase p72(Syk) (Syk) in platelets. Here we show that collagen and a collagen-related peptide (CRP), which binds to GPVI but does not bind to the integrin alpha2beta1, induced Btk tyrosine phosphorylation in platelets. Aggregation, dense granule secretion and calcium mobilisation were significantly diminished but not completely abolished in platelets from XLA patients in response to collagen and CRP. These effects were associated with a reduction in tyrosine phosphorylation of PLCgamma2. In contrast, aggregation and secretion stimulated by thrombin in Btk-deficient platelets were not significantly altered. Our results demonstrate that Btk is important for collagen signalling via GPVI, but is not essential for thrombin-mediated platelet activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778529     DOI: 10.1016/s0960-9822(98)70471-3

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  60 in total

1.  Genes required for B cell development.

Authors:  Mary Ellen Conley
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

2.  In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies.

Authors:  S Nisitani; R M Kato; D J Rawlings; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 3.  How will B-cell-receptor-targeted therapies change future CLL therapy?

Authors:  Jeffrey A Jones; John C Byrd
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

4.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

5.  Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets.

Authors:  Soochong Kim; Pierre Mangin; Carol Dangelmaier; Rivka Lillian; Shaun P Jackson; James L Daniel; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

6.  B cells delay neutrophil migration toward the site of stimulus: tardiness critical for effective bacillus Calmette-Guérin vaccination against tuberculosis infection in mice.

Authors:  Tatiana K Kondratieva; Elvira I Rubakova; Irina A Linge; Vladimir V Evstifeev; Konstantin B Majorov; Alexander S Apt
Journal:  J Immunol       Date:  2009-12-18       Impact factor: 5.422

7.  Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.

Authors:  Bhanu Kanth Manne; Rachit Badolia; Carol Dangelmaier; Johannes A Eble; Wilfried Ellmeier; Mark Kahn; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

Review 8.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

9.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

10.  Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.

Authors:  Rachel A Rigg; Joseph E Aslan; Laura D Healy; Michael Wallisch; Marisa L D Thierheimer; Cassandra P Loren; Jiaqing Pang; Monica T Hinds; András Gruber; Owen J T McCarty
Journal:  Am J Physiol Cell Physiol       Date:  2015-12-09       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.